As previously reported, Oppenheimer analyst Hartaj Singh upgraded Regeneron to Outperform from Perform, with a $410 price target, as he believes the company is now on the cusp of strong 2019/20 sales growth with increased Eylea penetration in DME in 2018/19, the NPDR indication expansion in late 2019, approval/launch of dupilumab in asthma in late 2018 and the approval/launch of cemiplimab in advanced CSCC in Q3. With OPEX increases potentially slowing, starting in 2019, the analyst believes Regeneron could "follow up the left jab of accelerating sales with the right hook of operating leverage."